BMO Capital Markets reissued their outperform rating on shares of DexCom, Inc. (NASDAQ:DXCM) in a research report released on Thursday.
A number of other research analysts have also recently issued reports on the company. Robert W. Baird reaffirmed a hold rating and set a $79.00 price objective on shares of DexCom in a research note on Sunday, September 10th. Wedbush reaffirmed an outperform rating and set a $76.00 price objective (down from $85.00) on shares of DexCom in a research note on Thursday. BidaskClub raised DexCom from a hold rating to a buy rating in a research note on Wednesday, June 21st. Cowen and Company reaffirmed a buy rating and set a $90.00 price objective on shares of DexCom in a research note on Friday, July 14th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $87.00 price objective on shares of DexCom in a research note on Friday, September 8th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating to the company. The company has an average rating of Buy and an average target price of $75.38.
Shares of DexCom (NASDAQ:DXCM) traded up 7.33% on Thursday, reaching $48.77. The company’s stock had a trading volume of 8,062,061 shares. The stock has a 50 day moving average of $72.62 and a 200-day moving average of $73.86. DexCom has a 12 month low of $45.61 and a 12 month high of $94.24. The firm’s market cap is $4.22 billion.
DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.07. DexCom had a negative return on equity of 27.90% and a negative net margin of 10.27%. The firm had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. During the same period last year, the firm earned ($0.24) earnings per share. The company’s revenue for the quarter was up 24.3% compared to the same quarter last year. On average, analysts anticipate that DexCom will post ($0.79) EPS for the current year.
WARNING: “DexCom, Inc. (DXCM) Receives Outperform Rating from BMO Capital Markets” was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/09/29/dexcom-inc-dxcm-receives-outperform-rating-from-bmo-capital-markets.html.
In other DexCom news, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $69.47, for a total transaction of $100,731.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 6,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 20th. The shares were sold at an average price of $69.34, for a total transaction of $416,040.00. The disclosure for this sale can be found here. Insiders sold 32,223 shares of company stock valued at $2,285,138 over the last 90 days. 1.70% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA increased its stake in shares of DexCom by 111.6% during the second quarter. BNP Paribas Arbitrage SA now owns 9,471 shares of the medical device company’s stock valued at $693,000 after purchasing an additional 4,995 shares in the last quarter. State of Wisconsin Investment Board increased its stake in shares of DexCom by 29.0% during the second quarter. State of Wisconsin Investment Board now owns 68,511 shares of the medical device company’s stock valued at $5,012,000 after purchasing an additional 15,420 shares in the last quarter. Morgan Stanley increased its stake in shares of DexCom by 18.0% during the first quarter. Morgan Stanley now owns 2,092,962 shares of the medical device company’s stock valued at $177,336,000 after purchasing an additional 319,631 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of DexCom by 9.0% during the second quarter. Victory Capital Management Inc. now owns 146,661 shares of the medical device company’s stock valued at $10,729,000 after purchasing an additional 12,135 shares in the last quarter. Finally, Credit Suisse AG increased its stake in shares of DexCom by 0.3% during the first quarter. Credit Suisse AG now owns 302,130 shares of the medical device company’s stock valued at $25,599,000 after purchasing an additional 791 shares in the last quarter.
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DexCom Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.